Introduction to SNORD115-24, A Potential Drug Target (G100036563)

Target Name: SNORD115-24

NCBI ID: G100036563

SNORD115-24

Other Name(s): HBII-52-24 | Small nucleolar RNA, C/D box 115-24 | small nucleolar RNA, C/D box 115-24

Introduction to SNORD115-24, A Potential Drug Target

SNORD115-24, also known as Small Nucleolar RNA SNORD115-24, is a class of molecules categorized as small nucleolar RNAs (snoRNAs). SnoRNAs are a type of non-coding RNA that primarily exist in the nucleoli of eukaryotic cells. They play important roles in the modification and processing of other RNA molecules, primarily ribosomal RNA (rRNA) and messenger RNA (mRNA). SNORD115-24 has recently gained attention in the field of medical research as a potential drug target and biomarker for various diseases. This article aims to explore the significance of SNORD115-24 and its potential applications in medicine.

SNOs as Modulators of Gene Expression

SnoRNAs, including SNORD115-24, are involved in various cellular processes, particularly in the modification of other RNA molecules. They function by guiding a group of proteins known as small nucleolar ribonucleoproteins (snoRNPs) to specific target sites on rRNA or mRNA. Once bound to the target molecule, snoRNPs facilitate the addition of chemical modifications such as methylation or pseudouridylation.

With regards to SNORD115-24, it has been shown to be involved in the modification of rRNA, specifically at the 18S rRNA. This modification contributes to the proper functioning of the ribosome and, consequently, the translation of mRNA into protein. Dysregulation of SNORD115-24 expression has been linked to abnormalities in ribosome biogenesis and protein synthesis, ultimately leading to various diseases.

SNORD115-24 as a Drug Target

The aberrant expression or function of SNORD115-24 has been implicated in several diseases, making it an intriguing target for therapeutic intervention. For instance, studies have highlighted the involvement of SNORD115-24 in neurodevelopmental disorders, particularly Prader-Willi Syndrome (PWS). PWS is a genetic disorder characterized by intellectual disability, hyperphagia, and other developmental abnormalities. SNORD115-24 is located within the genomic region known as the Prader-Willi critical region, and its deletion or dysfunction contributes to the pathogenesis of PWS.

By targeting SNORD115-24, it may be possible to modulate its expression or function, thereby potentially alleviating the symptoms associated with PWS. Novel therapeutic strategies such as antisense oligonucleotides (ASOs) or small molecule inhibitors could be developed to target SNORD115-24 and restore normal ribosomal function. However, further research is needed to fully understand the underlying mechanisms and validate SNORD115-24 as a viable drug target.

SNORD115-24 as a Biomarker

In addition to its potential as a drug target, SNORD115-24 shows promise as a biomarker for various diseases. Biomarkers are measurable indicators present in biological samples that can provide insight into the presence, progression, or severity of a disease.

Several studies have identified dysregulated expression of SNORD115-24 in different diseases. For example, in patients with colorectal cancer, SNORD115-24 was found to be significantly downregulated compared to healthy individuals. This alteration in expression levels suggests the potential use of SNORD115-24 as a diagnostic biomarker for colorectal cancer. Similarly, dysregulation of SNORD115-24 has been observed in other cancers, including breast cancer and lung cancer. Monitoring the expression levels of SNORD115-24 may help in the early detection and prognosis of these malignancies.

Furthermore, SNORD115-24 has shown promise as a biomarker in neurological disorders. In addition to its involvement in PWS, dysregulation of SNORD115-24 has been reported in patients with Angelman Syndrome (AS) and Prader-Willi-like syndrome (PWLS). These findings suggest that SNORD115-24 expression levels could potentially serve as a diagnostic or prognostic biomarker for these neurodevelopmental disorders. However, further studies are needed to validate these associations and establish standardized protocols for its measurement.

Conclusion

As our understanding of the role of SNORD115-24 in cellular processes and disease pathogenesis continues to expand, it becomes increasingly apparent that this small nucleolar RNA holds great potential as a drug target and biomarker. By manipulating its expression or function, we may be able to develop effective therapeutic strategies for diseases such as Prader-Willi Syndrome and certain cancers. Additionally, measuring SNORD115-24 expression levels could aid in the diagnosis and prognosis of various diseases, bringing us closer to personalized medicine. Continued research in this field will undoubtedly unveil the full potential of SNORD115-24 as a valuable tool in clinical practice.

Protein Name: Small Nucleolar RNA, C/D Box 115-24

The "SNORD115-24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD115-24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets